Table 2 Baseline clinical characteristics of the study population in BCAPS
Variable | Placebo/Placebo | Metoprolol/Placebo | Fluvastatin/Metoprolol | Fluvastatin/Placebo |
|---|---|---|---|---|
Number of participants | 117 | 118 | 117 | 120 |
Female (%) | 78 (66.7) | 78 (66.1) | 70 (59.8) | 72 (60.0) |
Age, mean (SD), years | 61.5 (5.7) | 60.3 (5.6) | 62.3 (5.0) | 61.8 (5.4) |
Height, mean (SD), cm | 168 (10) | 167 (8) | 169 (8) | 169 (9) |
Body Mass Index, Mean (SD), kg/m2 | 25.5 (3.6) | 25.5 (3.6) | 25.1 (2.7) | 25.7 (3.7) |
LDL-C, mean (SD), mmol/L | 4.07 (0.86) | 4.18 (0.92) | 4.15 (0.88) | 4.16 (0.82) |
HDL-C, mean (SD), mmol/L | 1.48 (0.40) | 1.39 (0.37) | 1.41 (0.35) | 1.37 (0.35) |
IMTmean CCA, median (IQR) | 0.88 (0.78-0.96) | 0.88 (0.77-0.99) | 0.86 (0.79-0.98) | 0.86 (0.78-0.97) |
IMTmax Bulb median (IQR) | 1.74 (1.46-2.09) | 1.77 (1.49-2.24) | 1.84 (1.52-2.29) | 1.81 (1.55-2.17) |
Growth Hormone - males, median (IQR), μg/L | 0.28 (0.06-0.84) | 0.15 (0.06-0.35) | 0.15 (0.06-0.97) | 0.18 (0.08-0.57) |
Growth Hormone - females, median (IQR), μg/L | 1.49 (0.58-3.14) | 1.52 (0.49-2.64) | 1.16 (0.53-2.32) | 1.53 (0.68-2.74) |